An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A Veterans Affairs clinic in Asheville has joined a larger national study testing whether a drug similar to Ozempic can help treat alcohol addiction. The study is enrolling people who drink heavily to see if giving them this medication reduces alcohol use compared with a placebo (a fake treatment). This is part of a wider push to see if medicines originally developed for weight loss and diabetes can help with other conditions. The drug in question is part of a family called GLP-1 receptor agonists. A common brand name people know is Ozempic (used for diabetes) and Wegovy (used for weight loss). In plain terms, these medicines act like a gut hormone that talks to the brain and can reduce appetite, slow stomach emptying, and change reward signals. They’re not alcohol itself or a traditional “alcohol medicine” — they’re repurposed drugs that might change the brain’s response to cravings or the pleasure from drinking. What the trial aims to show is whether people given this Ozempic-type drug drink less than similar people given a placebo. The Asheville VA is one of many sites contributing patients to the larger randomized controlled trial, which is the gold standard for testing a drug’s effect. We don’t have results yet; joining the study is about gathering rigorous data. Past early research and theory suggest these drugs could blunt cravings or reduce drinking in some people, but evidence so far is mixed and mostly limited to small studies or animal work. Why this matters is practical. Alcohol use disorder is common and hard to treat, and current medications don’t help everyone. If a widely used diabetes/weight-loss drug can safely lower alcohol use, it would give doctors another tool — especially useful in systems like the VA where many patients struggle with drinking. People interested would include patients with heavy drinking patterns, their families, and clinicians looking for more treatment options. There are important caveats. These drugs have side effects like nausea, vomiting, and in rare cases more serious issues; they’re approved for specific uses (diabetes, obesity) but not yet for alcohol use, which is why the study is needed. We don’t know if the benefit, if any, would last long-term or who benefits most. People on certain medications or with certain medical conditions might not be eligible. Being in a trial also means you might get a placebo instead of the active drug. Bottom line: The Asheville VA is helping test whether an Ozempic-type medicine can reduce heavy drinking, but we’ll need the full trial results before anyone can say if it’s a safe and effective treatment for alcohol addiction.
Source: 828 News Now